JVS: The natural course of anti-thrombosis treatment of acute arterial thrombosis in children

Acute femoral artery thrombosis (IFAT) can occur in critically ill newborns and infants who require arterial retention needles for monitoring or as a result of catheter surgery.
recommends anticoagulant therapy, but there is limited evidence to support optimal treatment time and ultrasound (US) monitoring.
the purpose of this study is to describe the dynamics of thrombosis and to determine the appropriate anticoagulant time and monitoring interval.
methodology This is a single-center retrospective queue study of children with acute IFAT between 2011 and 2019.
reviewed medical records and vascular laboratory studies.
included in the US ≥ 1 patient.
researchers defined the dissolution of blood clots as an ultrasound that confirmed no material echo in the cavity.
the dissolution time of the thrombosis using Kaplan-Meier (KM) analysis.
54 limbs were diagnosed with acute IFAT in 50 patients.
9.9 weeks (IQR: 3.1 to 21.7) and a medium weight of 4.2 kg (IQR: 3.3 to 5.5).
(65%) in patients with acute IFAT showed a decrease in foot Doppler ultrasound, mostly after heart catheter surgery (55%).
48 (89%) limb arteries were completely closed, 48% of which did not see blood flow below the ankle.
received US for each limb was 3 (range: 2 to 7), and 61% of limbs were monitored by US within 7 days of diagnosis.
anticoagulant therapy, 33% and 64% of patients were expected to have a complete dissolution of the thrombosis within 14 and 30 days, respectively.
9 patients (17%) did not receive anticoagulant therapy, of which only 2 patients IFAT dissolved.
diagnosis, one patient underwent an open thrombosis due to anticoagulant taboos and the other received thrombosis treatment.
no cases of tissue loss or amputation.
-term effect of anticoagulant therapy on the total pair IFAT.
the observed dissolution rate, it should be monitored every two weeks after the onment of anticoagulant therapy.
when anticoagulant therapy is used, one-third of patients are expected to dissolve blood clots every two weeks.